Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia - CC-90009-AML-002

Updated: 26 March, 2021   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • 12

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: CC-90009 in combination with gilteritinib
Drug: Gilteritinib
Experimental: CC-90009 in combination with venetoclax and azacitidine
Drug: CC-90009 Drug: Venetoclax Drug: Azacitidine

Key Eligibility Criteria

Inclusion Criteria: 1. Adult subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 2. Arm A (CC-90009 + venetoclax/azacitidine): 1. Newly diagnosed AML and is ≥ 75 years of age or intensive chemotherapy ineligible OR 2. Refractory AML and is ≥ 18 years of age 3. Arm B (CC-90009 + gilteritinib): 1. Subject is ≥ 18 years of age. 2. FLT3-ITD positive relapsed or refractory AML. 3. Gilteritinib treatment naïve 4. Subject has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. 5. Subject must have the following screening laboratory values: - Total White Blood Cell count (WBC) < 25 x 10^9 prior to study treatments. Treatment with hydroxyurea to achieve this level is allowed. - Selected electrolytes within normal limits or correctable with supplements. - Participant must have adequate liver function as demonstrated by: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) and bilirubin ≤ 1.5 x ULN - Participant has adequate renal function as demonstrated by an estimated serum creatinine clearance of ≥ 60 mL/min using the Cockcroft-Gault equation. 6. Agree to follow the CC-90009 Pregnancy Prevention Plan (PPP) and combination agents' requirements. Exclusion Criteria: 1. Subject with acute promyelocytic leukemia (APL) 2. Subject has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment 3. Patients with prior autologous hematopoietic stem cell transplant (HSCT) who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant related side effects) 4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing 5. Subject on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted 6. Subject has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2 7. Subject has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening. 8. Disorders or conditions disrupting normal calcium homeostasis or preventing calcium supplementation. 9. Impaired cardiac function or clinically significant cardiac diseases, including any of the following: 1. Left ventricular ejection fraction (LVEF) < 45% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO). 2. Complete left bundle branch or bifascicular block. 3. Congenital long QT syndrome. 4. Persistent or clinically meaningful ventricular arrhythmias. 5. QTcF ≥ 470 ms (Arm A) or > 450 ms (Arm B) on Screening electrocardiogram (ECG) 6. Unstable angina pectoris or myocardial infarction ≤ 6 months prior to starting study treatments or unstable arrhythmia. 7. Cardiovascular disability status of New York Heart Association Class ≥2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain. 10. Subject is a pregnant or lactating female 11. Additional exclusion criteria based on combination agent: a. For Combination Arm A (venetoclax/azacitidine): - Received strong or moderate CYP3A inhibitors or inducers or P-gp inhibitors within 7 days prior to initiation of first venetoclax dose. - Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to first venetoclax dose through last dose of venetoclax. 12. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1. a. Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment. 13. Previous SARS-CoV-2 vaccine within 14 days of C1D1.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com